IFNB1 and myeloid sarcoma: Further, MS patients have a lower abundance of the gut bacteria, Prevotella, compared to HC and the levels of Prevotella are increased in patients that receive disease-modifying therapies such as Copaxone® or Interferon beta (IFN-β) (7–9, 12).